Click Here to
Subscribe
Breaking
News, Updates,
& More
Stay Up
to Date

Abemaciclib, a New CDK4/CDK6 Inhibitor, Added to Fulvestrant Extends PFS in Advanced HR-Positive, HER2-Negative Breast Cancer

TOP - November 2017, Vol 10, No 4 - Breast Cancer
Phoebe Starr

Chicago, IL—The addition of the investigational CDK4/CDK6 inhibitor abemaciclib to fulvestrant (Faslodex) extended progression-free survival (PFS) by 7 months in women with hormone receptor (HR)-positive, HER2-negative advanced breast cancer, reported George W. Sledge, Jr, MD, Professor, Medical Oncology, Stanford University Medical Center, Palo Alto, CA, who presented the results of a large study at the 2017 ASCO annual meeting.

The median PFS increased from 9.3 months with fulvestrant alone to 16.4 months when abemaciclib was added, a 45% reduced risk for disease progression or death favoring the combination therapy. A consistent advantage for the combination was observed across all of the prespecified subgroups.

“Abemaciclib plus fulvestrant was an effective treatment for women with HR-positive, HER2-negative advanced breast cancer whose disease progressed on prior endocrine therapy. Abemaciclib dosed on a continuous schedule was generally well-tolerated,” said Dr Sledge. These results were also published in the Journal of Clinical Oncology to coincide with his talk.

MONARCH-2 Clinical Trial

The double-blind, phase 3, MONARCH-2 clinical trial enrolled 669 women with HR-positive, HER2-negative advanced breast cancer resistant to hormone therapy. Women were recruited at 142 centers in 19 countries and were randomized in a 2:1 ratio to the combination of abemaciclib plus fulvestrant or fulvestrant plus placebo. The initial dose of abemaciclib was 200 mg twice daily, which was reduced to 150 mg twice daily because of reported diarrhea with the higher dose in the first 178 women. Fulvestrant was dosed at 500 mg twice daily.

At a median follow-up of 19.5 months, the median PFS was 16.4 months with abemaciclib plus fulvestrant versus 9.3 months with fulvestrant plus placebo (P <.0001).

The objective response rate was doubled with the addition of abemaciclib (48.1%) versus fulvestrant monotherapy (21.3%).

“The response rate is, to the best of our knowledge, the highest recorded in an endocrine-resistant population,” said Dr Sledge.

An intent-to-treat analysis showed that the average reduction in tumor size was doubled with the combination (35%) versus fulvestrant (16.1%; P <.001). The median duration of response was not yet reached in the combination arm versus 25.6 months in the fulvestrant arm.

The combination was associated with a higher incidence of all-grade adverse events compared with fulvestrant plus placebo, including diarrhea (86.4% vs 24.7%, respectively) and neutropenia (46% vs 4%, respectively). Patients in the abemaciclib-containing arm also reported increased rates of abdominal pain, anemia, leukopenia, decreased appetite, and vomiting. The most common grade 3 or 4 adverse events with the combination treatment versus fulvestrant were neutropenia (26.5% vs 1.7%, respectively) and diarrhea (13.4% vs 0.4%).

Diarrhea occurred early in the treatment course, predominantly during the first treatment cycle, and appeared to be related to the dose of abemaciclib. Once the abemaciclib dose was reduced, severe diarrhea was rare.

Adverse events led to dose reduction in 42.9% of patients in the combination arm versus 1.3% in the fulvestrant plus placebo arm; the study drug was discontinued because of adverse events in 15.9% and in 3.1% of patients, respectively.

Based on these positive results in patients with advanced breast cancer, a phase 3 clinical trial of abemaciclib and endocrine therapy is planned for the adjuvant setting.

Which CDK4/CDK6 Inhibitor to Use?

Abemaciclib joins palbociclib (Ibrance) and ribociclib (Kisqali) as CDK4/CDK6 inhibitors that demonstrate a PFS advantage in patients with HR-positive, HER2-negative advanced breast cancer when combined with endocrine therapy.

CDK4/CDK6 inhibitors will most likely not have a role as monotherapy, said Ingrid Mayer, MD, Associate Professor of Medicine, Division of Hematology/Oncology, Vanderbilt University Medical Center, Nashville, TN, who discussed the study results.

Clinicians should select therapy based on 2 scenarios, using data from the MONARCH-2 clinical trial and from phase 3 studies of palbociclib and ribociclib, advised Dr Mayer. The first scenario is second-line treatment with a CDK4/CDK6 inhibitor plus fulvestrant in patients with a long disease-free interval (ie, approximately 15 months) after developing acquired resistance to first-line endocrine therapy.

The second scenario involves patients with primary estrogen therapy resistance; for these patients she suggests combination therapy with a CDK4/CDK6 inhibitor plus an aromatase inhibitor as a first-line option, followed by fulvestrant as a second-line option.

The hope is that longer-term follow-up will show an overall survival benefit, but that has not happened yet.

Related Items
MONALEESA-7 Sets New Standard of Care for Premenopausal Women with Advanced Breast Cancer
Phoebe Starr
TON - August 2019, Vol 12, No 4 published on August 6, 2019 in Breast Cancer
Studies Show ACA Reduces Disparities and Increases Access to Earlier Diagnosis and Treatment
Phoebe Starr
TON - August 2019, Vol 12, No 4 published on August 6, 2019 in ASCO
FDA Unveils Pilot Program to Expand Access to Investigational Oncology Drugs
Phoebe Starr
TOP - August 2019, Vol 12, No 3 published on July 29, 2019 in ASCO
Studies Show ACA Reduces Disparities and Increases Access to Earlier Diagnosis and Treatment
Phoebe Starr
TOP - August 2019, Vol 12, No 3 published on July 29, 2019 in ASCO
Reduced-Intensity Chemotherapy for Frail Elderly Patients with Advanced Gastroesophageal Cancer
Phoebe Starr
TOP - August 2019, Vol 12, No 3 published on July 29, 2019 in Geriatric Cancer
Enzalutamide or Apalutamide Added to ADT Are 2 New Options for Hormone-Sensitive Prostate Cancer
Phoebe Starr
TOP - August 2019, Vol 12, No 3 published on July 29, 2019 in Prostate Cancer
Practice-Changing Results: Olaparib Maintenance Therapy Extends Progression-Free Survival in Metastatic Pancreatic Cancer with BRCA Mutations
Phoebe Starr
TOP - August 2019, Vol 12, No 3 published on July 29, 2019 in Pancreatic Cancer
Advances in Breast Cancer Treatments: Are We Extending Patients’ Survival?
Meg Barbor, MPH
JHOP - June 2019 Vol 9, No 2 published on June 6, 2019 in Breast Cancer, HOPA
Talzenna (Talazoparib) New PARP Inhibitor Approved for the Treatment of HER2-Negative Advanced Breast Cancer with Germline BRCA Mutation
Lisa A. Raedler, PhD, RPh, Medical Writer
2019 Fourth Annual Oncology Guide to New FDA Approvals published on June 5, 2019 in Breast Cancer, Drug Updates, FDA Approvals
FDA Expands Indication for Kadcyla to Include the Adjuvant Treatment of HER2-Positive Early Breast Cancer
Yvette Florio Lane
Web Exclusives published on May 14, 2019 in Breast Cancer, FDA Approvals, In the News
Last modified: November 21, 2017